Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.
Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease.
复制标题
镰状细胞病患者对 COVID-19 疫苗接种的 IgG 免疫反应增强。
DOI：
10.1111/bjh.18899
复制
发表时间：
2023
影响因子：
6.5
通讯作者：
Stowell,SeanR
中科院分区：
文献类型：
--
作者：
Nakahara,Hirotomo;Cheedarla,Narayanaiah;Verkerke,HansP;Cheedarla,Suneethamma;Wu,Shang-Chuen;Hendrickson,JeanneE;Chang,Andres;McLemore,MorganL;ElRassi,Fuad;Roback,JohnD;Neish,AndrewS;Fasano,RossM;Stowell,SeanR
镰状细胞病（SCD）患者被认为是免疫功能低下的，但SCD患者对SARS-CoV-2疫苗接种的抗体反应数据有限。我们研究了201名SCD成人和人口统计学匹配的非SCD对照者的抗SARS-CoV-2 IgG滴度和总体中和活性。出乎意料的是，与匹配的对照相比，SCD患者产生了更稳健和持久的COVID-19疫苗IgG应答，尽管两个队列的中和活性保持相似。这些发现表明，与普通人群相比，SCD患者在COVID-19疫苗接种后获得了类似的抗体应答，这对SCD患者的最佳疫苗接种策略具有意义。
Patients with sickle cell disease (SCD) are considered to be immunocompromised, yet data on the antibody response to SARS‐CoV‐2 vaccination in SCD is limited. We investigated anti‐SARS‐CoV‐2 IgG titres and overall neutralizing activity in 201 adults with SCD and demographically matched non‐SCD controls. Unexpectedly, patients with SCD generate a more robust and durable COVID‐19 vaccine IgG response compared to matched controls, though the neutralizing activity remained similar across both cohorts. These findings suggest that patients with SCD achieve a similar antibody response following COVID‐19 vaccination compared to the general population, with implications for optimal vaccination strategies for patients with SCD.